Court Denies Alnylam, Max Planck’s Request to Block Tuschl-I IP Prosecution in US | GenomeWeb

By Doug Macron

A court has denied a request by Alnylam Pharmaceuticals and the Max Planck Institute to block efforts by the University of Massachusetts, the Massachusetts Institute of Technology, and the Whitehead Institute for Biomedical Research to prosecute intellectual property at the heart of an ongoing legal battle, according to a court document released this week.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PLOS this week: genetic study of breast cancer in Egyptian families, mutations linked to cleft lip and palate, and more.

Council Bluffs, Iowa, schools are encouraging more girls to pursue STEM courses, according to the Associated Press.

Because of new open-access requirements, Gates Foundation-funded researchers can't publish in some top journals, Nature News reports.

In Science this week: deletion of one microRNA allows pluripotent stem cells to form embryonic and non-embryonic lineages, and more.